Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma-Reference-Cited by-同舟云学术

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Published:2023-12 Issue:12 Volume:13 Page:4748-4764
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Liu Yingqiang,Zhan Zhengsheng,Kang Zhuang,Li Mengyuan,Lv Yongcong,Li Shenglan,Tong Linjiang,Feng Fang,Li Yan,Zhang Mengge,Xue Yaping,Chen Yi^ORCID,Zhang Tao,Song Peiran,Su Yi,Shen Yanyan,Sun Yiming,Yang Xinying,Chen Yi,Yao Shanyan,Yang Hanyu,Wang Caixia,Geng Meiyu,Li Wenbin,Duan Wenhu,Xie Hua,Ding Jian

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference47 articles.

1. Dissecting and rebuilding the glioblastoma microenvironment with engineered materials;Wolf;Nat Rev Mater,2019

2. Challenges to curing primary brain tumours;Aldape;Nat Rev Clin Oncol,2019

3. Frontiers in the treatment of glioblastoma: past, present and emerging;Janjua;Adv Drug Deliv Rev,2021

4. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells;Klemm;Cell,2020

5. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank;Chuntova;Neuro Oncol,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances to address challenges in extracellular vesicle-based applications for lung cancer;Acta Pharmaceutica Sinica B;2024-09

2. Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas;Acta Pharmacologica Sinica;2024-06-04

3. A novel strategy for treating oncogene‐mutated tumors by targeting tumor microenvironment and synergistically enhancing anti‐PD‐1 immunotherapy;Cancer Communications;2024-02-09

4. Colony-stimulating factor 1 receptor: a novel target for cancer immunotherapy;Advances in Cancer Immunotherapy [Working Title];2024-01-24